FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2600107601> ?p ?o ?g. }

• W2600107601 endingPage "2606" @default.
• W2600107601 startingPage "2606" @default.
• W2600107601 abstract "2606 Background: CC-223 is an ATP-competitive inhibitor of the mTOR kinase, including both TORC1 and TORC2. CC-223 was selected to address resistance of rapamycin analogues mediated by TORC2 activation. Methods: Following establishment of the MTD (reported at ASCO 2012), subjects with select advanced, refractory solid tumors, including NSCLC, HCC, NET, GBM and breast were enrolled in expansion cohorts of up to 20 evaluable subjects. CC-223 was dosed at 45 mg once daily in 28 day cycles until disease progression. Results: As of 09 January, 2013, 101 solid tumor subjects have been treated, including NSCLC (26), HCC (25), NET (23), breast (14), and GBM (13). Results from the NSCLC, HCC, and GBM cohorts are reported here; NET results are reported separately. The most common (> 20%) related adverse events (all grades) were fatigue, rash, stomatitis, hyperglycemia, anorexia, nausea, vomiting and diarrhea. In addition, related serious adverse events included infection (1), pneumonitis (4), renal insufficiency (2) and pancreatitis (2). CC-223 dose reduction was required in > 50% of subjects with NSCLC and HCC, usually during cycle 1 or 2. Exposure-dependent TORC1 (p4EBP1) and TORC2 (pAKT) inhibition was observed across cohorts. mTOR pathway inhibition and/or decreased proliferation was demonstrated in paired tumor biopsies, but results were inconsistent. Reduction in glucose uptake (> 25% decrease in SUV) on PET imaging at day 15 was observed in 78% (14/18) of NSCLC and 69% (11/16) of HCC subjects. Partial tumor responses were observed in evaluable subjects with NSCLC (1/17; confirmed, treatment duration 36 weeks) and HCC (3/15; 1 confirmed, treatment duration 15 – 26 weeks). Disease control rate in the overall NSCLC cohort was 42% (11/26) and in the HCC cohort, 40% (10/25). GBM subjects underwent salvage resections on study and none were progression-free at 6 months. CC-223 was present in all (11/11) resected GBM tumors with plasma:tumor ratios of 16 - 77%, confirming transit across the blood-brain barrier. Conclusions: Encouraging signals of biomarker and clinical activity were observed in HCC and NSCLC. Due to the frequency of dose reductions, select additional cohorts will be enrolled at a starting dose of 30 mg QD. Clinical trial information: NCT01177397." @default.
• W2600107601 created "2017-04-07" @default.
• W2600107601 creator A5002142386 @default.
• W2600107601 creator A5010929324 @default.
• W2600107601 creator A5012150503 @default.
• W2600107601 creator A5021624793 @default.
• W2600107601 creator A5027896781 @default.
• W2600107601 creator A5028020706 @default.
• W2600107601 creator A5028472820 @default.
• W2600107601 creator A5028833538 @default.
• W2600107601 creator A5034376000 @default.
• W2600107601 creator A5038564847 @default.
• W2600107601 creator A5042065032 @default.
• W2600107601 creator A5047069710 @default.
• W2600107601 creator A5052765751 @default.
• W2600107601 creator A5055054082 @default.
• W2600107601 creator A5063511816 @default.
• W2600107601 creator A5067072967 @default.
• W2600107601 creator A5072971421 @default.
• W2600107601 creator A5076017612 @default.
• W2600107601 creator A5083373965 @default.
• W2600107601 creator A5088108919 @default.
• W2600107601 date "2013-05-20" @default.
• W2600107601 modified "2023-10-18" @default.
• W2600107601 title "Phase I expansion trial of an oral TORC1/TORC2 inhibitor (CC-223) in advanced solid tumors." @default.
• W2600107601 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.2606" @default.
• W2600107601 hasPublicationYear "2013" @default.
• W2600107601 type Work @default.
• W2600107601 sameAs 2600107601 @default.
• W2600107601 citedByCount "16" @default.
• W2600107601 countsByYear W26001076012013 @default.
• W2600107601 countsByYear W26001076012014 @default.
• W2600107601 countsByYear W26001076012015 @default.
• W2600107601 countsByYear W26001076012016 @default.
• W2600107601 countsByYear W26001076012018 @default.
• W2600107601 countsByYear W26001076012019 @default.
• W2600107601 countsByYear W26001076012021 @default.
• W2600107601 countsByYear W26001076012023 @default.
• W2600107601 crossrefType "journal-article" @default.
• W2600107601 hasAuthorship W2600107601A5002142386 @default.
• W2600107601 hasAuthorship W2600107601A5010929324 @default.
• W2600107601 hasAuthorship W2600107601A5012150503 @default.
• W2600107601 hasAuthorship W2600107601A5021624793 @default.
• W2600107601 hasAuthorship W2600107601A5027896781 @default.
• W2600107601 hasAuthorship W2600107601A5028020706 @default.
• W2600107601 hasAuthorship W2600107601A5028472820 @default.
• W2600107601 hasAuthorship W2600107601A5028833538 @default.
• W2600107601 hasAuthorship W2600107601A5034376000 @default.
• W2600107601 hasAuthorship W2600107601A5038564847 @default.
• W2600107601 hasAuthorship W2600107601A5042065032 @default.
• W2600107601 hasAuthorship W2600107601A5047069710 @default.
• W2600107601 hasAuthorship W2600107601A5052765751 @default.
• W2600107601 hasAuthorship W2600107601A5055054082 @default.
• W2600107601 hasAuthorship W2600107601A5063511816 @default.
• W2600107601 hasAuthorship W2600107601A5067072967 @default.
• W2600107601 hasAuthorship W2600107601A5072971421 @default.
• W2600107601 hasAuthorship W2600107601A5076017612 @default.
• W2600107601 hasAuthorship W2600107601A5083373965 @default.
• W2600107601 hasAuthorship W2600107601A5088108919 @default.
• W2600107601 hasConcept C126322002 @default.
• W2600107601 hasConcept C143998085 @default.
• W2600107601 hasConcept C197934379 @default.
• W2600107601 hasConcept C2777714996 @default.
• W2600107601 hasConcept C2778570526 @default.
• W2600107601 hasConcept C2779524853 @default.
• W2600107601 hasConcept C2779984678 @default.
• W2600107601 hasConcept C2780580376 @default.
• W2600107601 hasConcept C31760486 @default.
• W2600107601 hasConcept C535046627 @default.
• W2600107601 hasConcept C71924100 @default.
• W2600107601 hasConcept C90924648 @default.
• W2600107601 hasConceptScore W2600107601C126322002 @default.
• W2600107601 hasConceptScore W2600107601C143998085 @default.
• W2600107601 hasConceptScore W2600107601C197934379 @default.
• W2600107601 hasConceptScore W2600107601C2777714996 @default.
• W2600107601 hasConceptScore W2600107601C2778570526 @default.
• W2600107601 hasConceptScore W2600107601C2779524853 @default.
• W2600107601 hasConceptScore W2600107601C2779984678 @default.
• W2600107601 hasConceptScore W2600107601C2780580376 @default.
• W2600107601 hasConceptScore W2600107601C31760486 @default.
• W2600107601 hasConceptScore W2600107601C535046627 @default.
• W2600107601 hasConceptScore W2600107601C71924100 @default.
• W2600107601 hasConceptScore W2600107601C90924648 @default.
• W2600107601 hasIssue "15_suppl" @default.
• W2600107601 hasLocation W26001076011 @default.
• W2600107601 hasOpenAccess W2600107601 @default.
• W2600107601 hasPrimaryLocation W26001076011 @default.
• W2600107601 hasRelatedWork W2118982164 @default.
• W2600107601 hasRelatedWork W2140733229 @default.
• W2600107601 hasRelatedWork W2177195013 @default.
• W2600107601 hasRelatedWork W2243375749 @default.
• W2600107601 hasRelatedWork W2350328551 @default.
• W2600107601 hasRelatedWork W2528657105 @default.
• W2600107601 hasRelatedWork W2793160291 @default.
• W2600107601 hasRelatedWork W2995798573 @default.
• W2600107601 hasRelatedWork W3129704776 @default.
• W2600107601 hasRelatedWork W4313236518 @default.
• W2600107601 hasVolume "31" @default.

• next